The latest market analysis reveals a significant upward trend in the global catheter-directed thrombolysis market, which was valued at USD 454.8 million in 2023. The market is expected to experience robust growth, with a Compound Annual Growth Rate (CAGR) of 5.9%, projected to reach an estimated value of USD 808 million by 2033.
Catheter-directed thrombolysis is a cutting-edge, minimally invasive procedure that is transforming the treatment of blood clots. This advanced technique involves the precise delivery of thrombolytic agents directly to the clot site, ensuring rapid and effective dissolution of the clot while minimizing systemic side effects. The procedure’s unparalleled efficacy and safety profile have led to its widespread adoption in the medical community, offering a superior alternative to conventional clot treatments.
Grab Hold of the Sample Report Instantly…
Future Market Insights stated, “With an anticipated CAGR of 5.9%, the catheter-directed thrombolysis market is poised for significant expansion over the next decade.” This growth is attributed to continuous innovation in catheter-based technologies, expanding applications across various medical conditions, and a rising demand for minimally invasive procedures.
The escalating prevalence of conditions such as deep vein thrombosis (DVT) and pulmonary embolism (PE) has intensified the necessity for efficient and targeted treatment options, driving demand for catheter-directed thrombolysis procedures. Additionally, the preference for minimally invasive techniques among patients and healthcare providers, resulting in reduced hospital stays and quicker recovery times, is further propelling market growth.
The projected value of USD 808 million by 2033 underscores the market’s vast potential and the opportunities it presents for stakeholders in the healthcare industry, including medical device manufacturers, healthcare providers, and investors.
As the global catheter-directed thrombolysis market continues its expansion, key players in the sector are expected to concentrate on technological advancements, strategic collaborations, and geographic expansion to capitalize on this growth trajectory.
Top Highlights from the FMI’s Analysis of the Catheter-directed thrombolysis industry:
- The North American catheter-directed thrombolysis industry is expected to gain 53.4% market share, with the United States enjoying the leading position in the region and globe by attaining 47% in the global market.
- Although Europe’s market share is less than half of North America’s, i.e., Europe garnered a 24.1% market share in 2022. The region still holds a prominent position in the market.
- Germany leads the European market with a market share of 4.7%.
- Japan has a value share of 3.1%, attracting businesses to delve deep into the market for revenue prospects.
- Australia’s growth rate in the market, as estimated by FMI, is expected to be 5.2% CAGR over the forecast period.
- China is expected to expand at a robust pace of 7.1% over the forecast period.
- India, another Asian country, is expected to expand at a CAGR of 5.8% from 2023 to 2033.
- The United Kingdom is expected to expand at a CAGR of 4.1% over the forecast period.
- Under the delivery mode category, direct delivery to the blood clot segment is expected to garner a market share of more than 62.8% over the forecast period.
- Based on end users, the hospital segment is expected to grab a value share of more than 47.8%.
Receive the Detailed Full Report Now…
Key Players in the News:
- In August 2022, Boston Scientific Corporation obtained Obsidio, Inc., which is a privately-owned firm that has created Gel Embolic Material (GEM) technology for the coagulum of blood vessels in the peripheral circulatory system.
- In July 2020, iVascular S.L.U introduced its sergeant peripheral support catheter for patients suffering from peripheral artery disorder or difficult anatomy during interventional and diagnostic procedures. The device delivers brilliant pushability and torque capacity due to its tapered shaft design.
Some of the key participants present in the market include:
- AngioDynamics Inc.
- Boston Scientific Corporation
- iVascular SLU
- Straub Medical AG
Key Segments:
By Delivery Mode:
- Direct Delivery to Blood Clot Catheter-directed Thrombolysis
- Catheter-directed Thrombolysis by Positioning Medical Device at Clot Site
By Indication:
- Pulmonary Embolism (PE)
- Deep Vein Thrombosis (DVT)
- Strokes
- Other Indications
By End User:
- Hospitals
- Surgical Centers
- Radiology Clinics
By Region:
- North America
- Latin America
- Asia Pacific
- Middle East and Africa
- Europe
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube